



Turkey gut health update: latest trends in coccidiosis and necrotic enteritis

Vereecken Monita, DVM

TSPC, Chester

March 2026

Importance



2025 Turkey Industry Annual Report - Current Health Issues Facing the US Turkey Industry

Steven R. Clark, DVM^{1,2*}
Professional Veterinary Services Manager, Turkeys
Huvepharma, Inc.
Peachtree City, Georgia

Lindy Froebel, PhD
Sr. Vice President of Science and Policy
National Turkey Federation (NTF)
Washington, DC

Carrie Cremers, DVM, MAHM
Manager of Technical Service and Animal Welfare
President, Association of Veterinarians in Turkey Production (AVTP)
Jennie-O Turkey Store
Willmar, MN

¹Turkey Industry subcommittee chairman of the United States Animal Health Association Committee on Poultry and Other Avian Species.

²Clark, et.al. Turkey Industry Annual Report available since 2000 <www.usaha.org>

*Contact: steven.clark@huvepharma.us



Steven Clark, DVM Veterinary Technical Service Manager, Turkeys Huvepharma, Inc.

Importance



Table 1. Turkey health survey (August 2024 - 2025) of professionals in US turkey production (n = 21, head reporting = >201.4 million) ranking current disease issues (1= no issue to 5 = severe problem). Data on file.

Avian Metapneumovirus
Lack of approved, efficacious drugs
Avian Influenza, High Pathogenicity
Clostridial Dermatitis (Cellulitis)
Colibacillosis

Table 1. Turkey health survey (August 2022 - 2023) of professionals in US turkey production (n = 26, head reporting = 208.2 million) ranking current disease issues (1= no issue to 5 = severe problem). Data on file.

Issue	Score Average (1-5)
Lack of approved, efficacious drugs	4.6
Colibacillosis	4.5
Clostridial Dermatitis (Cellulitis)	3.7
TR-DFTR (Turkey R)	3.5
<i>Ornithobacterium rhinotracheale</i> (ORT)	3.5
<i>Salmonella</i>	3.5

Table 1. Turkey health survey (August 2018 - 2019) of professionals in US turkey production ranking current disease issues (1= no issue to 5 = severe problem). n=24.

Issue	Score Average (1-5)	Score Mode (1-5)
Lack of approved, efficacious drugs	4.5	5
Colibacillosis	3.9	5
Clostridial Dermatitis (Cellulitis)	3.7	5
<i>Ornithobacterium rhinotracheale</i> (ORT)	3.5	4
<i>Salmonella</i>	3.5	4

Importance



- Turkey veterinarians (42) from 9 countries
- Represented 109.1 million heads equivalent to 58% of the 189.0 million turkeys produced in Europe
- March 2024 and December 2025

The ten highest ranked health challenges identified by respondents were:

- | | |
|---|--------------------------|
| 1. Colibacillosis | 6. Poult enteritis |
| 2. Necrotic enteritis | 7. Coccidiosis |
| 3. HPAI (highly pathogenic avian influenza) | 8. Avian metapneumovirus |
| 4. ORT (Ornithobacterium rhinotracheale) | 9. Poult quality |
| 5. Lack of approved drugs | 10. Aggressive behaviour |

Importance




**European Turkey
Health Committee (ETHEC)**
Annual report 2025

**Current
Health Issues
in the European
Turkey Industry**



Coccidiosis




Eimeria species




- Different compared with chicken species
 - Lower area-specificity for the different species
 - Lesions are less typical and less distinctive
 - Oocysts are more similar
- What is used for species identification:
 - Gross and microscopic pathology
 - Pathogenicity
 - Pre-patent period
 - Oocysts dimensions (morphology of development forms)
 - Species specific immunity

Eimeria species in turkeys



E. meleagrititis



E. gallopavonis



E. meleagridis




E. adenoeides



E. dispersa



E. innocua



E. subrotunda

Lesions

Multiplication site

Coccidiosis in turkeys



PATHOGENIC

E. meleagrimitis

E. adenoeides / *E. meleagridis*
(KCH)

E. meleagridis (KR)

E. gallopavonis


LESS-PATHOGENIC

E. dispersa


E. innocua

(*E. subrotunda*)


Impact on performance




300.000 – 27 days



1.000.000 – 32 days





300.000 – 22 days



300.000 – 27 days

Diagnosis




What is clear?





- Pathogenic versus non pathogenic
- Location: mid intestine – caecal area





Eimeria meleagridis



E. meleagridis



Eimeria adenoeides




E. meleagridis





E. adenoeides

Eimeria gallopavonis



E. gallopavonis




Prevalence



- Sample collection



7 EU countries and UK
127 turkey farms



Age at sampling 1-15 weeks
Median age: 6 weeks
Diseased / Monitoring



Standardized protocol
Veterinarians/technicians

387 samples




Material and methods




- Sample investigation



All samples
Microscopy – McMaster
Counting – Identification



E. meleagrititis *E. adenoeides*



E. gallopavonis *E. meleagridis*



E. dispersa



E. innocua



qPCR – primers Vrba et al.,
2010




E. meleagrititis



E. adenoeides



E. gallopavonis



E. meleagridis



E. dispersa



E. innocua





Results



- Microscopic investigation



All samples
Microscopy – McMaster
Counting – Identification



In 269 of the 387 samples
oocysts could be detected.

OPG range in
positive farms

OPG range	% of positive samples
200-1000	25%
1000-10.000	27%
10.000-100.000	33%
>100.000	15%




Results



- Microscopic investigation



All samples
Microscopy – McMaster
Counting – Identification



95%

39%

10%

0%


53% mixed
infections

47% 1 *Eimeria*
(group)

Results



- PCR investigation



Prevalence data



- Differentiation – PCR analysis

		<i>E. meleagrimitis</i>	<i>E. meleagridis</i>	<i>E. adenoeides</i>	<i>E. dispersa</i>	<i>E. gallopavonis</i>	<i>E. innocua</i>
US	% Positive (n farms=40)	98	15	95	0	40	3
Canada	% Positive (n farms=33)	70	48	39	24	48	21
EU	% Positive (n farms=41)	76	29	16	10	24	0

Distribution and abundance of *Eimeria* species in commercial turkey flocks across Canada

Rachel K. Imai, John R. Barta

2019- *Can Vet J*

PCR identification and prevalence of *Eimeria* species in commercial turkey flocks of the Midwestern United States

Audrey F. Duff , W. N. Briggs, J. C. Bielke, K. E. McGovern, M. Trombetta, H. Abdullah, L. R. Bielke, and K. M. Chasser 

2022- *Poultry Science*


Department of Animal Sciences, The Ohio State University, Columbus, OH 43210 USA

Conclusions



- Different species- different ages
- Use of anticoccidials – till age of 10-12 weeks is the minimum period advisable to avoid outbreaks with pathogenic species
- *Eimeria meleagridis* most prevalent species

Necrotic enteritis




Case reports in turkeys- Europe



- Meat type and breeders
- Age
 - 4-7 weeks: Italy 53% -Norway 80% - Finland: 3-8w – (US 5w and 7-12w)
 - No outbreaks in turkeys younger than 2 weeks (age resistance?)
- Peak incidence
 - March-April (Kaldhusdal et al., 2021)

Current field infections





Predisposing factors

- *Eimeria meleagridis*
- Feed mill (Kaldhusdal et al., 2021)
- Flock size (Kaldhusdal et al., 2021)
- Sex: Males (Lyhs et al., 2013; Droual, 1995)
- Concurrent diseases –HE and ascaridia (Droual, 1995; Ramsubeik, 2023)

Clostridium perfringens



Characterization of *Clostridium perfringens* isolates from healthy turkeys and from turkeys with necrotic enteritis

U. Lyhs,*¹ P. Perko-Mäkelä,† H. Kallio,† A. Brockmann,* S. Heinikainen,‡
H. Tuuri,§ and K. Pedersen#

**Ruralia Institute, Seinäjoki Unit, University of Helsinki, Kampusranta 9C, FI-60320 Seinäjoki, Finland;*
†*Finnish Food Safety Authority Evira, Research and Laboratory Department, Production Animal*
and Wildlife Research Unit, PO Box 198, FI-60101 Seinäjoki, Finland; ‡*Finnish Food Safety Authority Evira,*
Research Department and Laboratory, Veterinary Bacteriology, PO Box 92, FI-70701 Kuopio, Finland;
§*Seinäjoki University of Applied Sciences, Business School, Koulukatu 41, FI-60100 Seinäjoki, Finland;*
and #*DTU National Food Institute, Mørkhøj Bygade 19, DK-2860 Søborg, Denmark*

Characteristics of *Clostridium perfringens* strains isolated from turkeys

Monita Vereecken*¹, Luca Bano², Jef Reichardt³, Wouter Depondt¹ and Koen De Gussem¹.

¹*Huvepharma NV, Antwerp, Belgium;*

²*Istituto Zooprofilattico Sperimentale delle Venezie, Treviso, Italy, 3 Chêne Vert, Moreac, France*



Pathogenicity markers of *Clostridium* spp. in commercial turkeys

Mario Saita¹, Luca Bano², Daniele D. Gallazzi¹

¹Dipartimento di Patologia Animale, Igiene e Sanità Pubblica Veterinaria.
Università di Milano, Italy

²Istituto Zooprofilattico Sperimentale delle Venezie. Treviso, Italy

Corresponding author: Dr. Luca Bano. Istituto Zooprofilattico Sperimentale delle Venezie, Laboratorio di Treviso. Viale Brigata Treviso 13/a, 31100 Treviso, Italy - Tel. + 39 0422 302302 - Fax: + 39 0422 421154 - Email: lbano@izsvenezie.it

Molecular characterization of *Clostridium perfringens* strains isolated from diseased turkeys in Italy

Davide Giovanardi, Ilenia Drigo, Beatrice De Vidi, Fabrizio Agnoletti, Laura Viel, Katia Capello, Giacomo Berto & Luca Bano

Clostridium perfringens



Characterization of *Clostridium perfringens* isolates from healthy turkeys and from turkeys with necrotic enteritis



Pathogenicity markers of *Clostridium* spp. in commercial turkeys

U. Lyhs,*¹ P. Perko

*Ruralia Institute, Seinäjoki University of Applied Sciences
 †Finnish Food Safety Authority
 and Wildlife Research Unit, PO Box 16, 00030
 Research Department and Laboratory, Helsinki
 ‡Seinäjoki University of Applied Sciences
 and #DTU National Institute of Research in Food Safety

Table 1
 The 2018 *C. perfringens* toxin-based typing scheme.^a

Toxinotype	α -toxin (<i>plc</i> or <i>cpa</i>)	β -toxin (<i>cpb</i>)	ϵ -toxin (<i>etx</i>)	ι -toxin (<i>iap</i> and <i>ibp</i>)	CPE (<i>cpe</i>)	NetB (<i>netB</i>)
A	+	-	-	-	-	-
B	+	+	+	-	-	-
C	+	+	-	-	±	-
D	+	-	+	-	±	-
E	+	-	-	+	±	-
F	+	-	-	-	+	-
G	+	-	-	-	-	+

^a The names of toxin structural genes are shown in parentheses.

Gallazzi¹

Università della Salute e del Benessere
 Clinica Veterinaria.

Treviso, Italy

Università delle Venezie, Laboratorio di
 Diagnostica Microbica
 31043 Montebelluna - Fax: + 39 0422 421154

Characteristics of *Clostridium perfringens* in healthy turkeys

Monita Vereecken^{*1}, Luca Bano², Jef Brouwer

¹Huvepharma NV, Antwerp, Belgium;

²Istituto Zooprofilattico Sperimentale delle Venezie, Treviso, Italy, 3 Chêne Vert, Moreac, France

David Gianfranceschi, Ilaria Drigo, Beatrice De Vidi, Fabrizio Agnoletti, Laura Viel, Katia Capello, Giacomo Berto & Luca Bano

Characteristics of *Clostridium perfringens* from diseased turkeys

Clostridium perfringens



Characterization of *Clostridium perfringens* isolates from healthy turkeys and from turkeys with necrotic enteritis

U. Lyhs,*¹ P. Perko-Mäkelä,† H. Kallio,† A. Brockmann,* S. Heinikainen,‡
H. Tuuri,§ and K. Pedersen#

*Ruralia Institute, Seinäjoki Unit, University of Helsinki, Kampusranta 9C, FI-60320 Seinäjoki, Finland;
†Finnish Food Safety Authority Evira, Research and Laboratory Department, Production Animal
and Wildlife Research Unit, PO Box
Research Department and Laboratory
‡Seinäjoki University of Applied Sciences
and #DTU National Food



Pathogenicity markers of *Clostridium* spp. in commercial turkeys

Mario Saita¹, Luca Bano², Daniele D. Gallazzi¹

¹Dipartimento di Patologia Animale, Igiene e Sanità Pubblica Veterinaria,
Università di Milano, Italy

ezie. Treviso, Italy

mentale delle Venezie, Laboratorio di
0422 302302 - Fax: + 39 0422 421154

All strains are Alpha toxin positive
Many are Beta2 positive but not all
NetB: only reported in Finland

Characteristics of *Clostridium* turkeys

Monita Vereecken*¹, Luca Bano², Jef Reichardt³, Wouter Depondt¹ and Koen De Gussem¹.

¹Huvepharma NV, Antwerp, Belgium;

²Istituto Zooprofilattico Sperimentale delle Venezie, Treviso, Italy, 3 Chêne Vert, Moreac, France

Clostridium perfringens strains isolated from diseased turkeys in Italy

Davide Giovanardi, Ilenia Drigo, Beatrice De Vidi, Fabrizio Agnoletti, Laura Viel, Katia Capello, Giacomo Berto & Luca Bano

Clostridium perfringens



- Susceptibility testing – MIC 50- & 90
 - Antimicrobials
 - Amoxicillin : 0.06 – 0.125
 - Doxycycline: 4 – 8
 - Lincomycin: 8 – 16
 - Penicillin: 0.25 – 0.25
 - Tylosin 0.5 – 0.5
 - Ionophores
 - Monensin : 2 – 2
 - Lasalocid : 4 – 4

Importance of
predisposing factors

Vereecken et al.,2022

Infection model

Hardy et al. *BMC Veterinary Research* (2020) 16:63
<https://doi.org/10.1186/s12917-020-2270-5>

BMC Veterinary Research

RESEARCH ARTICLE

Open Access

Developing an experimental necrotic enteritis model in turkeys - the impact of *Clostridium perfringens*, *Eimeria meleagridis* and host age on frequency of severe intestinal lesions



Simon P. Hardy¹, Sylvie L. Benestad², Inger Sofie Hammes², Torfinn Moldal², Bruce David³, John R. Barta⁴, Jean-Michel Reperant⁵ and Magne Kaldhusdal^{2*}













Fig. 1 Photos of small intestinal mucosa from turkeys. A: Score 0 (normal). B: Score 1 (mild changes: pale mucosa and increased amount of watery intestinal contents). C: Score 2 (moderate changes): swollen, pale villi. D-G: Score 3 (various sub-types of severe changes). H: Score 3 (mucosal depressions suggesting healing multifocal necrotic enteritis). Photos A-F and H: Simon P Hardy. Photo G: Magne Kaldhusdal



Experimental model for the reproduction of necrotic enteritis in turkeys using different *Clostridium perfringens* strains


B. Cordioli, M. Vereecken, I. Drigo, M. Garbuio, C. Zanardello, L. Gagliazzo, L. Palazzolo, L. Zandonà, A. Rizzardi, M. De Gussem, K. De Gussem & L. Bano



Strain differences in NE model



- Experimental reproduction of necrotic enteritis in turkeys



Strain differences in NE model




- Treatments



UC: Negative control- commercial diet



PC: Positive control- Predisposing diet
Eimeria meleagridis challenge



CP netB-
C. perfringens - netB negative
Origin: NE outbreak in turkeys



CP netB+
C. perfringens - netB positive
Origin: NE outbreak in chickens

Strain differences in NE model




- Treatments



UC: Negative control- commercial diet



PC: Positive control- Predisposing diet
Eimeria meleagridis challenge



CP netB-
C. perfringens - netB negative
Origin: NE outbreak in turkeys



CP netB+
C. perfringens - netB positive
Origin: NE outbreak in chickens

Challenge model: mortality up to 30% in chickens

Strain differences in NE model




- Treatments



UC: Negative control- commercial diet



PC: Positive control- Predisposing diet
Eimeria meleagridis challenge



CP netB-

C. perfringens - netB negative
Origin: NE outbreak in turkeys




CP netB+

C. perfringens - netB positive
Origin: NE outbreak in chickens

BUT6 turkeys

Challenge model: mortality up to 30% in chickens

Strain differences in NE model



- Mortality -> occurred on D41-42


GROUP	UC	PC	CP netB+	CP netB-
Dead birds	0	0	21	0
Total	24	26	26	26
Mortality	0.0%	0.0%	80.8%	0.0%



Strain differences in NE model



- Lesion scoring



T01: negative control

T02: high protein diet + *E. meleagrimitis*

T03: high protein diet + *E. meleagrimitis*
+ Cp *netB*-positive



T04: high protein diet + *E. meleagrimitis*
+ Cp *netB*-negative





Strain differences in NE model

- Successful reproduction is **strain dependent**
- Toxins involved in pathology?
 - Other toxins? TpeL?
 - Expression of netB?

Table 2. *Clostridium perfringens* strains used in the experimental reproduction of NE.

ID strain	Origin (age)	Toxinotype	NetB	TpeL	CPE	Beta-2
5454/1/14	Turkey (27 weeks)	A	Negative	Negative	Negative	Positive
E.13.51	Chicken (24 days)	A	Positive	Positive	Negative	Positive

- Eimeria as predisposing factor -> coccidiosis control

Control




- Coccidiosis and necrotic enteritis

Europe
Coccidiostats

US
Coccidiostats
Vaccines

Brand Name	Compound	Company	Dose (ppm)	WT (days)	Max.age (weeks)	Authorised until
Avatec	Lasalocid sodium	Phibro	75-125	5	16	Under revision
Elancoban	Monensin sodium	Elanco	60-100	1	16	Under revision
Monimax	Monensin/nicarbazin	Huvepharma	80-100	0	16	30/07/2030
Stenorol	Halofuginone	Huvepharma	2-3	3	12	04/02/2034
Coxidin	Monensin-sodium	Huvepharma	60-100	0	16	2036
Coxiril	Diclazuril	Huvepharma	0.8-1.2	0	-	04/02/2025



Thank you!



Questions?

WVPAC 2027

24th World Veterinary Poultry Association Congress

Brussels - Belgium

30 August - 3 September



Stay updated



www.wvpac2027.com